cas 936-52-7|| where to buy 4-(cyclopent-1-en-1-yl)morpholine

Nom du produit:4-(cyclopent-1-en-1-yl)morpholine

IUPAC Name:4-(cyclopent-1-en-1-yl)morpholine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM163851-25g	in stock	ƞŭŭ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 936-52-7 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:936-52-7; Formule moléculaire:C9H15NO; Point de fusion:-; Code SMILES:N1(C2=CCCC2)CCOCC1; Densité:

: Numéro de catalogue:CM163851; Poids moléculaire:153.23; Point d'ébullition:; N° Mdl:; Stockage:

: Morpholines; Morpholine contains secondary amine groups and has all the typical reactive characteristics of secondary amine groups. It can react with inorganic acids to form salts, and react with organic acids to form salts or amides, which can be subjected to alkylation reaction, and can also be reacted with ethylene oxide, ketone or Willgerodt reaction. Morpholine is a six-membered ring containing oxygen and nitrogen, and its alkalinity is much lower than that of its parent piperidine. The marketed morpholine drugs are mainly distributed in the fields of tumors, cardiovascular and cerebrovascular diseases, respiratory system diseases, digestive system diseases, infectious diseases and mental disorders.; morpholine price; if you are interested in morpholine price, please feel free to contact us. More information of our products will be forwarded to you upon receipt of your specific inquiry.

: Etrasimod; Etrasimod is a new generation of oral S1P receptor modulator, which can specifically bind to S1P receptors 1, 4, and 5. It is being studied for a range of immune inflammatory diseases, including ulcerative colitis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. At present, the highest stage of research and development of the drug is to apply for marketing, which is used to treat ulcerative colitis and is expected to be approved by FDA in this month.